Baker McKenzie has advised KBC Securities on the formation of a joint venture with Van Lanschot Kempen Investment Banking. KBC Securities, part of the KBC Group,...
KBC Securities and Van Lanschot Kempen Investment Banking Form ECM Joint Venture
ResInvest Acquires Onyx Power Group from Riverstone Holdings
Baker McKenzie has advised ResInvest Group on its acquisition of Onyx Power Group from Riverstone Holdings LLC. ResInvest Group has agreed to acquire Onyx Power Group...
Fagron Group’s Acquisition of Euro OTC & Audor Pharma GmbH
Baker McKenzie advised Fagron Group on the acquisition of Euro OTC & Audor Pharma GmbH. Fagron Group, an international market leader in pharmaceutical formulations, has acquired...
Galapagos’ Separation into Two Publicly Traded Entities
Baker McKenzie advised Galapagos on the deal. Galapagos plans to separate into two distinct publicly traded companies. As part of this separation, one entity will be...
ATB Therapeutics’ €54 Million Series A Financing Round
Baker McKenzie advised ATB Therapeutics SA on the deal. ATB Therapeutics SA, a Belgian next-generation antibody company, completed a EUR 54 million Series A financing. The...
Biocartis Group’s Enforcement by Secured Creditors
Baker McKenzie advised Biocartis Group NV and its group companies on the deal. Biocartis Group NV and its group companies executed an enforcement by Biocartis’s secured...
Galapagos’ Acquisition of CellPoint
Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
Mithra Pharmaceuticals’ €100 Million Equity Raising Fund
Baker McKenzie advised Mithra Pharmaceuticals on the deal. Mithra Pharmaceuticals executed a €100 million equity funding from Goldman Sachs International. Mithra is a listed Belgian biotech company...